A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 4, 2000, Pages 319-328

  Supko, Jeffrey G ^c   Lynch, Thomas J ^c   Clark, Jeffrey W ^c   Fram, Robert ^d   Allen, Lee F ^d   Velagapudi, Raja ^d   Kufe, Donald W ^a,b   Eder Jr , Joseph Paul ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Cemadotin; Chemotherapy; Clinical trials; Dolastatin; Pharmacokinetics

Indexed keywords

CEMADOTIN; DOLASTATIN; DOLASTATIN 15; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033775009     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000152     Document Type: Article

References (27)

1. The dolastatins
2. The dolastatins, a family of promising antineoplastic agents
3. Natural products which interact with tubulin in the Vinca alkaloid, maytansine, rhizoxin, phompsin A, dolastatins 10 and 15, and halichondrin B
4. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules
5. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15
6. Phase I trial of dolastatin-10 in patients with advanced solid tumors
7. Clinical trials referral resource. Clinical trials of dolastatin-10
8. Antineoplastic agents 360. Synthesis and cancer cell growth inhibtory studies of dolastatin 15 structural modifications
9. LU 103793 (NSC D-669,356): A synthetic peptide that interacts with microtubules and inhibits mitosis
10. In vitro cytotoxicity and mechanism of action of LU103793
11. Antitumor evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay
12. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines
13. Pre-clinical antitumor activity of a novel water-soluble dolastatin 15 analog (LU103793)
14. Phase I clinical and pharmacokinetic study of LU103793 (cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors
15. Clinical and pharmacologic phase I study of cemadotin-HCl (LU103793), a novel antimitotic peptide, given as a 24-h infusion in patients with advanced cancer
16. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced malignancies
17. Phase I clinical study of LU 103793 (cemadotin) given on a weekly x4 schedule
18. Phase I study to determine the safety of LU103793 as a 5-min IV inusion, every other day x3 every 3 weeks, in patients with malignant solid tumors
19. Accelerated titration designs for clinical phase I trials in oncology
20. Estimation of variance for harmonic mean half-lives
21. The jacknife - A review
22. A phase I, pharmacokinetic/pharmacodynamic study of dolastatin-10 in adult patients with advanced solid tumors
23. Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities
24. Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase I clinical trial